Management Of Tyrosine Kinase Inhibitor–Induced Hand–Foot Skin Reaction: Viewpoints from the Medical Oncologist, Dermatologist, and Oncology Nurse

Conflicts of interest: For E. M., none to disclose. C. R. has participated in advisory boards for Bayer, Roche, Pfizer, Astrazeneca, and GSK in the field of melanoma treatment and the management of the cutaneous side effects of anticancer agents. C. P. has acted as a paid adviser or speaker for Bayer Schering Pharma, Pfizer Oncology, Hoffman La Roche, Novartis Pharma, GSK, and Wyeth Pharmaceuticals and has received research funding from Bayer Schering Pharma and Novartis Pharma.

Correspondence to: Elizabeth Manchen, RN, MS, OCN, Section of Hematology/Oncology, University of Chicago Medical Center, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637; telephone: (773) 702–4135

¹ PubMed ID in brackets